IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Abingworth LLP

Q3 2018 Holdings

Filed 2018-11-14 | 16 holdings | $9.0M | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
Adaptimmune(ADAPY)SPONDS ADR00653A107$3.4M250,00037.6%
Cellectis(CLLS)SPONDS ADR15117K103$2.8M100,00031.3%
Aurinia Pharma(AUPH)Common05156V102$2.7M400,43429.4%
Crispr(CRSP)NAMEN AKTH17182108$54.9K1,237,2020.6%
SientraCommon82621J105$52.5K2,199,0120.6%
Verona(VRNA)SPONDS ADR925050106$11.3K901,9430.1%
ParatekCommon699374302$10.0K1,041,1310.1%
ObsevaCommonH5861P103$7.9K440,0000.1%
Chiasma(CHMA)Common16706W102$7.5K2,080,5950.1%
ProteonCommon74371L109$3.8K2,017,8720.0%
Cymabay(CBAYUSD)Common23257D103$3.0K273,4170.0%
Ultragenyx(RARE)Common90400D108$2.9K38,1000.0%
Sierra OncologyCommon82640U107$2.5K1,444,4450.0%
Aveo Pharma(AVEOEUR)Common053588109$1.3K400,0000.0%
Immune DesignCommon45252L103$1.2K352,3000.0%
HistogenixCommon43358V109$473888,8890.0%